These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 8673525)

  • 41. Induction of homologous virus neutralizing antibodies in guinea-pigs immunized with two human immunodeficiency virus type 1 glycoprotein gp120-iscom preparations. A comparison with other adjuvant systems.
    Sjölander S; Hansen JE; Lövgren-Bengtsson K; Akerblom L; Morein B
    Vaccine; 1996 Mar; 14(4):344-52. PubMed ID: 8744563
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction of antibodies against epitopes inaccessible on the HIV type 1 envelope oligomer by immunization with recombinant monomeric glycoprotein 120.
    Schønning K; Bolmstedt A; Novotny J; Lund OS; Olofsson S; Hansen JE
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1451-6. PubMed ID: 9824323
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteins.
    Rovinski B; Rodrigues L; Cao SX; Yao FL; McGuinness U; Sia C; Cates G; Zolla-Pazner S; Karwowska S; Matthews TJ
    AIDS Res Hum Retroviruses; 1995 Oct; 11(10):1187-95. PubMed ID: 8573374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
    Kothe DL; Decker JM; Li Y; Weng Z; Bibollet-Ruche F; Zammit KP; Salazar MG; Chen Y; Salazar-Gonzalez JF; Moldoveanu Z; Mestecky J; Gao F; Haynes BF; Shaw GM; Muldoon M; Korber BT; Hahn BH
    Virology; 2007 Mar; 360(1):218-34. PubMed ID: 17097711
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations in both gp120 and gp41 are responsible for the broad neutralization resistance of variant human immunodeficiency virus type 1 MN to antibodies directed at V3 and non-V3 epitopes.
    Park EJ; Vujcic LK; Anand R; Theodore TS; Quinnan GV
    J Virol; 1998 Sep; 72(9):7099-107. PubMed ID: 9696803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Generation and structural analysis of soluble oligomeric gp140 envelope proteins derived from neutralization-resistant and neutralization-susceptible primary HIV type 1 isolates.
    Stamatatos L; Lim M; Cheng-Mayer C
    AIDS Res Hum Retroviruses; 2000 Jul; 16(10):981-94. PubMed ID: 10890360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response.
    Quiñones-Kochs MI; Buonocore L; Rose JK
    J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High-titer HIV-1 neutralizing antibody response of rhesus macaques to gp160 and env peptides.
    Ronco J; Dedieu JF; Marie FN; Pinter A; Kaczorek M; Girard M
    AIDS Res Hum Retroviruses; 1992 Jun; 8(6):1117-23. PubMed ID: 1503824
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the immune response to recombinant gp120 in humans and chimpanzees.
    Berman PW; Eastman DJ; Wilkes DM; Nakamura GR; Gregory TJ; Schwartz D; Gorse G; Belshe R; Clements ML; Byrn RA
    AIDS; 1994 May; 8(5):591-601. PubMed ID: 7520248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cross-neutralizing antibodies in rabbits immunized with HIV-1 gp160 purified from simian cells infected with a recombinant vaccinia virus.
    Klaniecki J; Dykers T; Travis B; Schmitt R; Wain M; Watson A; Sridhar P; McClure J; Morein B; Ulrich JT
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):791-8. PubMed ID: 1742074
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fine specificity of anti-V3 antibodies induced in chimpanzees by HIV candidate vaccines.
    Coëffier E; Girard M; Barré-Sinoussi F; Meignier B; Muchmore E; Fultz PN; LeClerc C
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1023-34. PubMed ID: 9718117
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding Sites.
    Townsley S; Li Y; Kozyrev Y; Cleveland B; Hu SL
    J Virol; 2016 Jan; 90(2):829-41. PubMed ID: 26512079
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.
    Gorny MK; Williams C; Volsky B; Revesz K; Cohen S; Polonis VR; Honnen WJ; Kayman SC; Krachmarov C; Pinter A; Zolla-Pazner S
    J Virol; 2002 Sep; 76(18):9035-45. PubMed ID: 12186887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
    Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
    J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.
    Lubeck MD; Natuk RJ; Chengalvala M; Chanda PK; Murthy KK; Murthy S; Mizutani S; Lee SG; Wade MS; Bhat BM
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1443-9. PubMed ID: 7888199
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adjuvanticity of stearyl tyrosine on the antibody response to peptide 503-535 from HIV gp160.
    Nixon A; Zaghouani H; Penney CL; Lacroix M; Dionne G; Anderson SA; Kennedy RC; Bona CA
    Viral Immunol; 1992; 5(2):141-50. PubMed ID: 1616585
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Resistance to human immunodeficiency virus 1 infection of SCID mice reconstituted with peripheral blood leukocytes from donors vaccinated with vaccinia gp160 and recombinant gp160.
    Mosier DE; Gulizia RJ; MacIsaac PD; Corey L; Greenberg PD
    Proc Natl Acad Sci U S A; 1993 Mar; 90(6):2443-7. PubMed ID: 8460155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.